145 related articles for article (PubMed ID: 34656041)
1. Positioning of an unprecedented 1,5-oxaza spiroquinone scaffold into SMYD2 inhibitors in epigenetic space.
Dhorma LP; Teli MK; Nangunuri BG; Venkanna A; Ragam R; Maturi A; Mirzaei A; Vo DK; Maeng HJ; Kim MH
Eur J Med Chem; 2022 Jan; 227():113880. PubMed ID: 34656041
[TBL] [Abstract][Full Text] [Related]
2. Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
Venkanna A; Cho KH; Dhorma LP; Kumar DN; Hah JM; Park HG; Kim SY; Kim MH
Eur J Med Chem; 2019 Feb; 163():453-480. PubMed ID: 30530196
[TBL] [Abstract][Full Text] [Related]
3. Antifolate and antiproliferative activity of 6,8,10-triazaspiro[4.5]deca-6,8-dienes and 1,3,5-triazaspiro[5.5]undeca-1,3-dienes.
Ma X; Chui WK
Bioorg Med Chem; 2010 Jan; 18(2):737-43. PubMed ID: 20036565
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
Zhang B; Liao L; Wu F; Zhang F; Sun Z; Chen H; Luo C
Bioorg Med Chem Lett; 2020 Nov; 30(22):127598. PubMed ID: 33011288
[TBL] [Abstract][Full Text] [Related]
5. Positioning of an unprecedented spiro[5.5]undeca ring system into kinase inhibitor space.
Venkanna A; Subedi L; Teli MK; Lama PD; Nangunuri BG; Lee SY; Kim SY; Kim MH
Sci Rep; 2020 Dec; 10(1):21265. PubMed ID: 33277542
[TBL] [Abstract][Full Text] [Related]
6. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies.
San José-Enériz E; Agirre X; Rabal O; Vilas-Zornoza A; Sanchez-Arias JA; Miranda E; Ugarte A; Roa S; Paiva B; Estella-Hermoso de Mendoza A; Alvarez RM; Casares N; Segura V; Martín-Subero JI; Ogi FX; Soule P; Santiveri CM; Campos-Olivas R; Castellano G; de Barrena MGF; Rodriguez-Madoz JR; García-Barchino MJ; Lasarte JJ; Avila MA; Martinez-Climent JA; Oyarzabal J; Prosper F
Nat Commun; 2017 May; 8():15424. PubMed ID: 28548080
[TBL] [Abstract][Full Text] [Related]
7. Discovery of new LXRβ agonists as glioblastoma inhibitors.
Chen H; Chen Z; Zhang Z; Li Y; Zhang S; Jiang F; Wei J; Ding P; Zhou H; Gu Q; Xu J
Eur J Med Chem; 2020 May; 194():112240. PubMed ID: 32248003
[TBL] [Abstract][Full Text] [Related]
8. Identification and Characterizations of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Scaffold Hopping- and 2D-Molecular Fingerprint-Based Similarity Search.
Ding H; Lu WC; Hu JC; Liu YC; Zhang CH; Lian FL; Zhang NX; Meng FW; Luo C; Chen KX
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498708
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
Thaler F; Varasi M; Abate A; Carenzi G; Colombo A; Bigogno C; Boggio R; Zuffo RD; Rapetti D; Resconi A; Regalia N; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
Eur J Med Chem; 2013 Jun; 64():273-84. PubMed ID: 23644210
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer.
Wu Z; Bai Y; Jin J; Jiang T; Shen H; Ju Q; Zhu Q; Xu Y
Eur J Med Chem; 2021 May; 217():113357. PubMed ID: 33740547
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract][Full Text] [Related]
12. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
[TBL] [Abstract][Full Text] [Related]
13. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Nguyen H; Allali-Hassani A; Antonysamy S; Chang S; Chen LH; Curtis C; Emtage S; Fan L; Gheyi T; Li F; Liu S; Martin JR; Mendel D; Olsen JB; Pelletier L; Shatseva T; Wu S; Zhang FF; Arrowsmith CH; Brown PJ; Campbell RM; Garcia BA; Barsyte-Lovejoy D; Mader M; Vedadi M
J Biol Chem; 2015 May; 290(22):13641-53. PubMed ID: 25825497
[TBL] [Abstract][Full Text] [Related]
14. Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2.
Eggert E; Hillig RC; Koehr S; Stöckigt D; Weiske J; Barak N; Mowat J; Brumby T; Christ CD; Ter Laak A; Lang T; Fernandez-Montalvan AE; Badock V; Weinmann H; Hartung IV; Barsyte-Lovejoy D; Szewczyk M; Kennedy S; Li F; Vedadi M; Brown PJ; Santhakumar V; Arrowsmith CH; Stellfeld T; Stresemann C
J Med Chem; 2016 May; 59(10):4578-600. PubMed ID: 27075367
[TBL] [Abstract][Full Text] [Related]
15. New class of azaheptapyridine FPT inhibitors as potential cancer therapy agents.
Zhu HY; Desai J; Cooper AB; Wang J; Rane DF; Kirschmeier P; Strickland C; Liu M; Nomeir AA; Girijavallabhan VM
Bioorg Med Chem Lett; 2014 Feb; 24(4):1228-31. PubMed ID: 24462667
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
[TBL] [Abstract][Full Text] [Related]
17. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
Liu F; Barsyte-Lovejoy D; Li F; Xiong Y; Korboukh V; Huang XP; Allali-Hassani A; Janzen WP; Roth BL; Frye SV; Arrowsmith CH; Brown PJ; Vedadi M; Jin J
J Med Chem; 2013 Nov; 56(21):8931-42. PubMed ID: 24102134
[TBL] [Abstract][Full Text] [Related]
18. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
Rabal O; San José-Enériz E; Agirre X; Sánchez-Arias JA; de Miguel I; Ordoñez R; Garate L; Miranda E; Sáez E; Vilas-Zornoza A; Pineda-Lucena A; Estella A; Zhang F; Wu W; Xu M; Prosper F; Oyarzabal J
J Med Chem; 2021 Mar; 64(6):3392-3426. PubMed ID: 33661013
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel diazaspirodecanone derivatives containing piperidine-4-carboxamide as chitin synthase inhibitors and antifungal agents.
Ji Q; Li B; Chu Y; Wu H; Du C; Xu Y; Shen Y; Deng J
Bioorg Chem; 2021 Sep; 114():105108. PubMed ID: 34175721
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
